CDNF as a Drug Target: Unlocking the Potential of ARMETL1 (G441549)

Target Name: CDNF

NCBI ID: G441549

CDNF

CDNF as a Drug Target: Unlocking the Potential of ARMETL1

CDNF (Cadherin-associated protein F) is a protein that plays a crucial role in cell-cell adhesion, which is a fundamental process in various biological processes, including embryonic development, tissue repair, and cancer progression. CDNF has also been implicated in various diseases, including cancer, neurodegenerative disorders, and developmental delays. As a result, targeting CDNF has emerged as a promising strategy for the development of new therapeutic approaches.

ARMETL1: A Key Player in CDNF Signaling

ARMETL1 (Arsenical-modified Metallothionein L1) is a protein that was first identified as a potential biomarker for cancer. It is a 21-kDa transmembrane protein that is expressed in various tissues, including adipose tissue, muscle, and brain. ARMETL1 has been shown to play a critical role in modulating cellular signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established signaling pathway that is involved in various cellular processes, including cell growth, differentiation, and inflammation. It is a key pathway for cancer development and progression, and ARMETL1 has been shown to be involved in its regulation.

ARMETL1 functions as a negative regulator of the TGF-β pathway by inhibiting the activity of the transcription factor SMAD2. SMAD2 is a key regulator of the TGF-β pathway, and its inhibition by ARMETL1 leads to increased TGF-β signaling activity, which can lead to the formation of cancerous tumors.

In addition to its role in TGF-β signaling, ARMETL1 has also been shown to regulate various other signaling pathways, including the PI3K/Akt pathway and the NF-kappa-B pathway. These signaling pathways are involved in various cellular processes, including cell survival, angiogenesis, and inflammation.

CDNF as a Potential Drug Target

The potential of ARMETL1 as a drug target is due to its involvement in various cellular processes that are involved in cancer development and progression. As a negative regulator of the TGF-β pathway, ARMETL1 has been shown to inhibit the formation of cancerous tumors, and its inhibition has been shown to result in the regression of established cancerous tumors.

In addition, ARMETL1 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Its inhibition has been shown to improve cognitive function in animal models of these disorders.

The Role of CDNF in ARMETL1 Function

CDNF is a protein that is involved in the regulation of various cellular processes, including TGF-β signaling, PI3K/Akt signaling, and NF-kappa-B signaling. It has been shown to play a critical role in the regulation of ARMETL1 activity, and its inhibition has been shown to result in the inhibition of ARMETL1 function.

CDNF functions as a negative regulator of the TGF-β pathway by binding to the transcription factor SMAD2 and inhibiting its activity. This inhibition of SMAD2 activity by CDNF has been shown to result in increased TGF-β signaling activity, which can lead to the formation of cancerous tumors.

In addition, CDNF has also been shown to regulate the PI3K/Akt pathway by binding to the protein p120, which is a negative regulator of the PI3K pathway. This regulation by CDNF has been shown to result in the inhibition of the activity of p120, which can lead to increased PI3K signaling activity.

CDNF also

Protein Name: Cerebral Dopamine Neurotrophic Factor

Functions: Trophic factor for dopamine neurons. Prevents the 6-hydroxydopamine (6-OHDA)-induced degeneration of dopaminergic neurons. When administered after 6-OHDA-lesioning, restores the dopaminergic function and prevents the degeneration of dopaminergic neurons in substantia nigra (By similarity)

The "CDNF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDNF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets